Biogen
Work Here?
About Biogen
Industries
Biotechnology
Healthcare
Company Size
10,001+
Company Stage
IPO
Total Funding
$2M
Headquarters
Cambridge, Massachusetts
Founded
1978
Overview
Simplify's Take
What believers are saying
- Leqembi's approval in multiple countries boosts Biogen's global market presence.
- AI-driven personalized medicine enhances Biogen's treatment outcomes for Alzheimer's patients.
- Strategic acquisitions and partnerships expand Biogen's competitive edge and growth potential.
What critics are saying
- Biogen's reliance on Leqembi poses risks if safety issues arise.
- Regulatory setbacks in the EU could delay Leqembi's market entry.
- Intensifying competition in Alzheimer's treatments may impact Biogen's market share.
What makes Biogen unique
- Biogen's Leqembi is the only FDA-approved anti-amyloid therapy for Alzheimer's.
- Biogen's strategic partnerships enhance its drug discovery and development capabilities.
- Biogen's investment in digital health technologies supports real-time patient monitoring.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$2M
Above
Industry Average
Funded Over
1 Rounds
Benefits
Remote Work Options
Professional Development Budget
Company News
Biogen Inc. has been determined as a "Top Pick" in the biopharma sector due to its strong financial fundamentals, strategic positioning, and promising growth prospects.
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapyTOKYO and CAMBRIDGE, Mass., Jan. 26, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has approved the Supplemental Biologics License Application (sBLA) for once every four weeks lecanemab-irmb (U.S
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option. TOKYO and CAMBRIDGE, Mass., Jan. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S
Cambridge, Mass. – January 9, 2025 – Biogen Inc. (Nasdaq: BIIB) – today announced the appointment of Adam Feire, Ph.D., as Head of Business Development and External Innovation. Mr. Feire reports to Adam Keeney, Ph.D., Executive Vice President and Head of Corporate Development. In this role, Mr
Cambridge, Mass. - January 9, 2025 - Biogen Inc. (Nasdaq: BIIB) - today announced the appointment of Adam Feire, Ph.D., as Head of Business Development and External Innovation.
Biogen is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Biogen
Industries
Biotechnology
Healthcare
Company Size
10,001+
Company Stage
IPO
Total Funding
$2M
Headquarters
Cambridge, Massachusetts
Founded
1978
Biogen is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today